FDA Pulls Authorization for GSK-Vir’s COVID Therapy, Sotrovimab, as BA.2 Cases Rise

The U.S. health regulator said on Tuesday GlaxoSmithKline (GSK.L) and Vir Biotechnology’s (VIR.O) antibody therapy was no longer authorized as a COVID-19 treatment, with data suggesting it was unlikely to be effective against the dominant Omicron sub-variant in the country.

Drug Information for COVID-19 Monoclonal Antibody (Bebtelovimab) and COVID-19 Polyclonal Antibody Evusheld (Tixagevimab-Cilgavimab) Available on ApoThera Clinical Decision Support App

Drug Info: ApoThera Drug Disease Clinical Support App